Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma. - Wikidata - wikimedia - TriplyDB

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.

http://www.wikidata.org/entity/Q36712741

about

Advances in Primary Central Nervous System Lymphoma.Efficacy and safety of pemetrexed on recurrent primary central nervous system lymphomas in China: a prospective study Central nervous system involvement by Waldenström macroglobulinaemia (Bing-Neel syndrome): a multi-institutional retrospective study.Recent advances in treatment of primary central nervous system lymphoma.Methotrexate re-challenge for recurrent primary central nervous system lymphoma Management of elderly patients with primary central nervous system lymphoma.Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.Recurrent or refractory primary central nervous lymphoma: therapeutic considerations.Present and future treatment options for primary CNS lymphoma.Ibrutinib Unmasks Critical Role of Bruton Tyrosine Kinase in Primary CNS Lymphoma.Primary central nervous system lymphoma: essential points in diagnosis and management.High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group.Immunochemotherapy using rituximab (RTX) and high-dose methotrexate (HD-MTX): an evaluation of the addition of RTX to HD-MTX in recurrent primary central nervous system lymphoma (PCNSL).Primary CNS Lymphoma.The Diagnosis and Treatment of Primary CNS Lymphoma Rapid infusion rituximab is well tolerated in patients with primary CNS lymphoma

P2860

Q31007237-6106FD0E-84DD-4BF9-B9DC-83DDB1B754C8 Q33714119-65FD448F-79E8-499E-9F93-811DC2233234 Q33824350-2FCD43E6-0B59-4634-BB20-8B4BBD272D3F Q37345440-64C60175-CA2D-4246-AE8F-5C37DE2E4F66 Q37600487-8055812D-9A45-4164-A3A7-B38C7932FC68 Q38096927-6D4FC75F-09A4-4CC4-84DA-D58D69553A84 Q38119420-1AEED53C-2A34-460F-BAA0-6EE7DB4F0ED9 Q38140000-4F14F6CC-0052-497B-A7CE-A589B355BEBD Q38587122-B462A758-D14D-4B6B-A08C-804BAEB10CBA Q38723290-6D65799D-0C41-46D0-88FE-F2DE161EBAD8 Q39185721-D3CC38C0-22E2-4AD7-9509-CB80F2E2CA54 Q40179899-CD5D3DE0-87A6-45D3-9DDF-F679248F3AFA Q47692369-D19BB745-7E23-48FC-95D9-FB656D7F12B1 Q51841565-4279BE8E-BF3C-443E-B58B-007AF872771A Q56967801-EDBE476E-8694-48DD-A602-D74D3DCC2964 Q58728525-E9D21E7E-96AA-4F22-B2B9-7F5210778D7E

P2860

Multicenter phase II study of rituximab and temozolomide in recurrent primary central nervous system lymphoma.

http://www.wikidata.org/entity/Q36712741

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Multicenter phase II study of ...... ntral nervous system lymphoma.

@ast

Multicenter phase II study of ...... ntral nervous system lymphoma.

@en

type

label

Multicenter phase II study of ...... ntral nervous system lymphoma.

@ast

Multicenter phase II study of ...... ntral nervous system lymphoma.

@en

prefLabel

Multicenter phase II study of ...... ntral nervous system lymphoma.

@ast

Multicenter phase II study of ...... ntral nervous system lymphoma.

@en

P1433

Q36712741-E3167B71-0AF7-4585-8C65-B671A3232667

P1476

Q36712741-9063FAC1-DCA0-4399-918C-B34F570E32F7

P2093

Q36712741-013669F3-BE17-4A03-AFEC-4D4E4A6E5233

Q36712741-4965BA6E-1FD6-4775-B39D-6B62366D6BD4

Q36712741-4AD299C8-2F09-4D83-977C-4ADE20424C43

Q36712741-61F8C800-981B-4832-BD3C-187AAC86DF86

Q36712741-859B0C78-6781-436A-9DFB-3B9DB68A4A31

Q36712741-85E3833D-4D32-4D21-9DF3-CFF2862B4F6B

Q36712741-9C381AE4-326B-4B2F-939F-52CB13A56DAE

Q36712741-C297836B-12B7-46AF-87AA-DF2AE67BDEAC

Q36712741-CD50AE3D-03CE-4688-B63E-9DD9A0B0AB60

P2860

Q36712741-0B8AA67A-28A5-4C5A-8CAE-CCB71008AD56

Q36712741-1D3FA595-F4B1-4E40-B159-FD8867EBCCFC

Q36712741-22FF4291-DEC5-4AC0-B04A-CC1838DF6A3A

Q36712741-44445F08-00E4-41D6-9B5E-E2662C09AB17

Q36712741-51388937-093D-4F89-9C5C-69D45AD6A179

Q36712741-90708740-A329-4675-8BD1-9A688CD771C5

Q36712741-A37E73A4-8269-488A-A741-65742307FC5F

Q36712741-A6F8B668-056A-4B62-8296-D60BA2423664

Q36712741-AE337399-01AC-470F-83E1-A575F0D8B4DD

Q36712741-DD5A687B-1C4D-4796-A1C2-15649F937100

P304

Q36712741-FB89ED30-D7C7-47DA-827D-1210300AD100

P31

Q36712741-56B2388D-F7F0-48B4-BEBE-321A866BF9C0

P356

Q36712741-6E786E9E-B733-4FCA-8482-210CBF0E4DD4

P433

Q36712741-31F0B50E-A839-47F8-BD7E-1FDB6EE51273

P478

Q36712741-6861546C-BC80-4106-A5EB-652222DF5275

P50

Q36712741-3A5DD1F5-C2C0-4453-A89B-528943648412

P577

Q36712741-EA18FFFF-82F0-44A5-B3CF-C101E2D60F03

P698

Q36712741-26243BB7-FE08-4ED2-B854-F7739B99CB2E

P921

Q36712741-ADFFD111-126F-49A1-997F-488CADFE34A2

P932

Q36712741-59BF2A81-0DD6-4D17-B4D2-C73E526EDC20

P356

10428194.2012.698736

P1433

Leukemia & Lymphoma

P1476

Multicenter phase II study of ...... ntral nervous system lymphoma.

@en

P2093

Antonio Omuro

http://www.w3.org/2001/XMLSchema#string

Jan Drappatz

http://www.w3.org/2001/XMLSchema#string

Lakshmi Nayak

http://www.w3.org/2001/XMLSchema#string

Lauren E Abrey

http://www.w3.org/2001/XMLSchema#string

Lisa M Deangelis

http://www.w3.org/2001/XMLSchema#string

Mark R Gilbert

http://www.w3.org/2001/XMLSchema#string

Michael Prados

http://www.w3.org/2001/XMLSchema#string

North American Brain Tumor Consortium

http://www.w3.org/2001/XMLSchema#string

Patrick Y Wen

http://www.w3.org/2001/XMLSchema#string

P2860

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.

Prospective trial on topotecan salvage therapy in primary CNS lymphoma.

Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.

Salvage treatment with temozolomide in refractory or relapsed primary central nervous system lymphoma and assessment of the MGMT status.

Pharmacotherapy for primary CNS lymphoma: progress beyond methotrexate?

Rituximab monotherapy for patients with recurrent primary CNS lymphoma.

Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide.

Temozolomide as salvage treatment in primary brain lymphomas.

Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire.

P304

58-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.698736

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

54

http://www.w3.org/2001/XMLSchema#string

P50

David A Reardon

P577

2012-07-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22656234

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4802006

http://www.w3.org/2001/XMLSchema#string